Merger news has revived this penny stock 🙌

*Together with

Good day, 360 –

Here are our top 3 trade ideas today – these setups look primed!  Be the best prepared trader on the Street...and please throw some love to our Sponsor alts.co today —  thank you 🫶

VBLT - 80% higher on merger news

LUNR - 2nd day play, low float Intuitive Machines closes up 116%

NVDA - 10% higher after beating on the top and bottom line

VBLT - 80% higher on merger news

Vascular Biogenics (VBLT) announced this morning that it had entered into a definitive merger agreement with Notable Labs that is expected to close in Q2 of 2023.

The merger would also include a $10.3 million investment from Notable prior to closure of the deal leaving the combined company with cash runway into 2025.

Prior to this announcement, VBLT had a market cap of just $9.38 million according to Finviz based on yesterday’s close.

The pre-market high was $0.2580 and would be the first major target for bulls.

Above it, the first major resistance level is $0.2730, with $0.30, $0.4 and $0.4777 above that. Above that there is a lot of gap to fill and $1 would be a psychological level.

Below $0.2580 there is potential support at $0.2050, $0.1817 with $0.1490 below that.

LUNR - 2nd day play, low float Intuitive Machines (LUNR) closes up 116%

After running over 250% on Thursday, LUNR consolidated for 2 days before closing up over 116% yesterday. The stock is gapping another 30% higher this morning in the pre-market.

LUNR has a float of just over 4 million shares according to Finviz and is having wild moves on light volume.

The $90-$93 level was an area of support yesterday and should be an important pivot level today.

Above it, targets to the upside are $120, and then yesterday’s high of $136. Above $136 there is blue sky, and no telling how high this can go. We’ve seen stocks like this in the past go $1000+ so risk management is key here.

Below $90, there is a gap to fill to $81.99, and the next potential support levels are $73 with $50 and then $40 below that. 

NVDA - 10% higher after beating on the top and bottom line 

Nvidia (NVDA) reported Q4 EPS of $0.88 vs the $0.81 analyst estimate. Revenue came in at $6.05 billion vs the $6.01 billion consensus estimate for Q4. NVDA also guided Q1 2023 revenue of $6.5 billion vs the $6.33 billion consensus. It should be noted that NVDA is also an A.I. play as A.I. and machine learning relies heavily on graphics chips.

The $226 was resistance in the after hours and becomes potential support today.

Above it the first major target is $230/$230.50 where NVDA failed on 2 previous occasions. Above that, there is a gap to fill at $242.08 and $250 becomes a short term psychological target.

Below $226 the next target to the downside is $220, followed by $210 and a gap to fill at $207.54.

Economic Calendar (EST)

8:30am Initial jobless claims

8:30am Chicago fed activity.

10:30am Natural gas report

10:50am Fed speaker Bostic

11:00am EIA petroleum report

11:00am Fed mfg index

2:00pm Fed speaker Daly

Earnings for Today (After Market)

AAOI, ACA, ACCO, ADSK, ALKT, ALRM, ALTR, AMEH, AMH, ATSG, BALY, BBDC, BCOV, BECN, BIGC, BKNG, BLI, BOOM, BTE, BWMX, BWXT, BYND, CABO, CDXS, CE, CENX, CHE, CIB, COLL, CRC, CTO, CUBE, CVNA, CWK, CYRX, DAIO, DH, DVAX, EFC, EGO, EIX, ENV, EOG, ERF, ERIE, EXFY, FND, FOXF, FTAI, FTCH, GDOT, GDYN, GH, GLPI, GPMT, GSBD, INFN, INGN, INT, INTU, IRTC, KAMN, KOF, KTOS, KURA, KWR, LASR, LAW, LMAT, LNT, LPRO, LSI, LYV, LZ, MAIN, MAX, MCW, MDRX, MELI, MNKD, MORN, MP, MRIN, MTZ, NOG, NTST, NVEE, NVTS, OII, OLED, OPEN, OPK, ORC, ORGN, PAY, PBA, PEN, PLYA, PODD, PRDO, PRI, PRTA, PSNL, PSTV, RCEL, RCKY, RHP, RVLV, SEM, SG, SPNT, SPXC, SQ, STTK, SWN, TMST, TUSK, UPLD, UVE, VAPO, VICI, VICR, WBD, WISH, XNCR, ZETA, ZEUS

Top Headlines

FOLD: Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

ISR: Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

ABBV: AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

AZN: AstraZeneca to pay KYM $63M upfront in license deal for potential gastric cancer therapy

WLDS: Wearable Devices to Showcase its AI-Based Air-Touch Technology for Apple Ecosystem at MWC Barcelona 2023

MAXR: Maxar Launches High-Performance SYNTH3D Digital Twin for Metaverse, Simulation and Virtual Reality Applications

MSFT: Microsoft wants to cut up to 120 jobs in Germany -WIW0

BIOL: Biolase enters the skin resurfacing market in the U.S. with the launch of a new waterlase fractional handpiece

DEN: Aqualung Carbon Capture Announces Denbury as Strategic Investor

PERF: Perfect Corp. Unveils 2023 Upgrade to AI Skin Analysis Solution, Adding Real-Time Skin Concern Detection, Skincare Product Suggestions and Routine Recommendations, Further Enhancing the Industry-Leading Solution

SO: Southern Company announces offering of $1.5 billion in aggregate principal amount of Convertible Senior Notes due December 15, 2025

SWI: SolarWinds Expands Global Reach of World-Class SaaS Observability Solution to Help Customers Accelerate Digital Transformation and Reduce IT Complexity

VBLT: VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

INAB: IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue

GNPX: Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

MEIP: MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

ALDX: Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy

OMGA: Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

AVIR: Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

HRZN: Monroe Capital Announces Agreement to Acquire Horizon Technology Finance Management, Market Leader in Venture Lending

NEM: Newmont Announces Increased 2022 Mineral Reserves of 96 Million Gold Ounces and 68 Million Gold Equivalent Ounces

MRNA: Moderna forecasts 2023 covid vaccine sales below market expectations

PSN: Parsons Awarded $30 Million to Improve Water Quality, Seismic Stability, and Safety for Valley Water

DPRO: Vermeer Partners with Draganfly to Offer Enhanced Mission Capabilities in GPS-Denied and Spoofed Environments for the Defense Industry

To Your Success!

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions